Findings

What do systematic reviews say?

7 questions · 7 findings · 4 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 14.3%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 28.6%Moderate 4 · 57.1%High 0 · 0%

Oral vs IV antibiotics

All‐cause mortality · people with cancer who have febrile neutropenia

Oral showed no clear difference in mortality compared with intravenous antibiotic therapy (moderate certainty).

1 finding from 1 review

Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients 2013 · Cochrane Headline outcomes only
RR 0.95 [0.54, 1.68]
9 studies · 1392 participants
Moderate

Direct oral anticoagulant (DOAC) prophylaxis vs no prophylaxis

All‐cause mortality · ambulatory people with cancer without venous thromboembolism receiving systemic therapy

Direct oral anticoagulant (DOAC) prophylaxis showed no clear difference in mortality compared with no prophylaxis (moderate certainty).

1 finding from 1 review

Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation 2021 · Cochrane Headline outcomes only
RR 0.94 [0.64, 1.38]
3 studies · 1440 participants
Moderate

Direct oral anticoagulant secondary prophylaxis vs Low molecular weight heparin secondary prophylaxis

All‐cause mortality · patients with cancer with venous thromboembolism

Direct oral anticoagulant secondary prophylaxis showed no clear difference in all‐cause mortality compared with low molecular weight heparin secondary prophylaxis (low certainty).

1 finding from 1 review

Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
RR 0.97 [0.83, 1.14]
5 studies · 2854 participants
Low

Direct oral anticoagulant secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

All‐cause mortality · patients with active cancer with venous thromboembolism

Direct oral anticoagulant secondary prophylaxis showed no clear difference in all‐cause mortality compared with vitamin K antagonist secondary prophylaxis (low certainty).

1 finding from 1 review

Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
RR 0.94 [0.72, 1.23]
4 studies · 1060 participants
Low

Vitamin K antagonist (VKA) prophylaxis vs no prophylaxis

All‐cause mortality · ambulatory people with cancer without venous thromboembolism receiving systemic therapy

Vitamin K antagonist (VKA) prophylaxis showed no clear difference in mortality compared with no prophylaxis (moderate certainty).

1 finding from 1 review

Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation 2021 · Cochrane Headline outcomes only
RR 0.95 [0.87, 1.03]
5 studies · 1281 participants
Moderate

Aspirin vs direct oral anticoagulants (DOAC)

All‐cause mortality ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents

The review found no eligible studies for this question.

1 finding from 1 review

Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Vitamin K antagonist (VKA) prophylaxis vs no prophylaxis

Mortality at 6 months: main analysis · ambulatory people with cancer without venous thromboembolism receiving systemic therapy

Vitamin K antagonist (VKA) prophylaxis showed no clear difference in mortality at 6 months: main analysis compared with no prophylaxis (moderate certainty).

1 finding from 1 review

Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation 2021 · Cochrane Headline outcomes only
RR 0.93 [0.77, 1.13]
3 studies · 946 participants
Moderate